Vera Therapeutics (VERA) Net Income towards Common Stockholders (2020 - 2026)

Vera Therapeutics (VERA) has 7 years of Net Income towards Common Stockholders data on file, last reported at -$288.2 million in Q1 2026.

• Quarterly Net Income towards Common Stockholders fell 365.36% year-over-year to -$288.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$607.0 million (down 198.13% YoY) and the FY2025 annual result came in at $62.9 million, up 6292000.0% from the prior year.
• Net Income towards Common Stockholders declined to -$288.2 million in Q1 2026, from -$144.8 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of -$17.7 million in Q1 2022 to a low of -$288.2 million in Q1 2026.
• A 5-year average of -$62.8 million and a median of -$38.6 million in 2023 frame the typical range for Net Income towards Common Stockholders.
• Annual changes were most pronounced in 2023 — Net Income towards Common Stockholders climbed 24.19% — and 2026, when it plunged 365.36%.
• Tracing VERA's Net Income towards Common Stockholders over 5 years: stood at -$33.2 million in 2022, then retreated by 15.99% to -$38.6 million in 2023, then retreated by 14.42% to -$44.1 million in 2024, then sank by 228.23% to -$144.8 million in 2025, then slumped by 99.04% to -$288.2 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$288.2 million (Q1 2026), -$144.8 million (Q4 2025), and -$81.4 million (Q3 2025), per Business Quant data.